tbuckley/cabot-search huggingface dataset:
REDUCED FLOW CAPACITY AS MEASURED BY CARDIAC POSITRON EMISSION TOMOGRAPHY PREDICTS VENTRICULAR TACHYARRHYTHMIA IN PATIENTS WITH AN ICD
Authors: Todd Rosenthal, Daniel Masvidal, Freddy Abi-Samra, Michael Bernard, Sammy Khatib, Glenn Polin, Paul Rogers, Robert Bober, Daniel Morin
Journal: Journal of the American College of Cardiology (2017)
INFLUENCE OF LOW VERSUS HIGH DOSE ON THE ASSOCIATION OF LOOP DIURECTIC AND MORTALITY IN PATIENTS WITH HEART FAILURE: INSIGHTS FROM THE UNITE-HF REGISTRY
Authors: Kirkwood F. Adams, Stephanie Dunlap, Amanda Lee, Ileana Pina, Adrian Van Bakel, J. Herbert Patterson, Todd Schwartz, Frank McGrew, Hector Ventura, Ron Oren
Journal: Journal of the American College of Cardiology (2017)
DOES STROKE RISK INFLUENCE THE DECISION TO ANTICOAGULATE POST PERCUTANEOUS CORONARY INTERVENTION PATIENTS WITH ATRIAL FIBRILLATION: A REVIEW OF 3850 PATIENTS
Authors: Kenneth Kita, Akash Rusia, Shawn Shah, Youning Zhang, Dipayon Roy, Jonathan Nattiv, Natasha Doshi, Han Tun, Leonardo Clavijo, Rahul N. Doshi
Journal: Journal of the American College of Cardiology (2017)
Incorrect Data Used in Statistical Analyses
Authors: Stuart A. Batterman, Eva L. Feldman
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Excellent survival of pediatric dermatofibrosarcoma protuberans in Taiwanese
Authors: C. Chien, Y. Chang, D. Lin, Z. Lin, R. Yang
Journal: Journal of Clinical Oncology (2006)

19512 Background: Pedicatric dermatofibrosarcoma protuberans (PDFSP) was a rare disease. We reported our institutional experience with PDFSP treated from 1977–2002. Methods: Twelve patients with PDFSP diagnosed before age 18 years were treated in our institute from 1977–2002 according to institutional cancer registry. After approved by institutional research ethic committee (ClinicalTrials.gov Identifier: NCT00173355 ), active patient contact and linkage with National Residency Registry was done to survey the disease status. Results: There were 6 boys and 6 girls in this study. The median age at diagnosis were 16 years (range: 3 months ∼18 years). The disease sites were diverse, from scalp to knee. Nine of them underwent wide excision in our hospital for their primary disease; the other 3 patients underwent wide excision in our hospital for local recurrent disease. None of them underwent neoadjuvant or adjuvant therapy. All of them had low grade T1a (≤ 5cm in size, superficially located) disease except T staging was not available in two patients. Negative margin was obtained in all in the operation of our instituion except close margin in one patient, who had uncontrolled recurrence and died of progressive disease later. The clinical follow-up (FU) period range from 1 to 214 months (median: 30). Active patients contact via telephone followed by twice postcard invitation was done. No evidence of disease (NED) was revealed by medical FU for three patients and by telephone FU for three patients. For the remaining six patients who had no response after telephone and postcards contact, data from linkage with National Residency Registry was used. Death was noted in one patient and aliveness was noted in five patients (all of them were NED in their last FU in our hospital). The 10-year/15-year progression free and overall survival rates were 100%/75% and 100%/83% respectively without obvious complications. Conclusion: The prognosis of PDFSP in Taiwanese was excellent when adequate surgical margin was obtained. No significant financial relationships to disclose.
A phase 1 dose finding study of CHR-2797, an inhibitor of M1 aminopeptidases, in patients with advanced solid tumours
Authors: A. Reid, A. Protheroe, G. Attard, C. Cowsill, J. Spicer, L. Vidal, E. Bone, L. Hooftman, A. Harris, J. S. De-Bono
Journal: Journal of Clinical Oncology (2006)

3053 Background: CHR-2797 is a novel, orally bioavailable inhibitor of the M1 family of aminopeptidases, in particular PuSA, and LTA 4 hydrolase. Exposure of cancer cells to CHR-2797 results in the generation of the active metabolite CHR-79888 which is poorly membrane-permeable, resulting in intracellular accumulation. CHR-2797 has shown anti-proliferative activity in syngeneic (rat) and xenograft (mouse) cancer models, and is anti-angiogenic in vitro. Methods: Patients (pts) (ECOG PS ≤ 2) with histologically confirmed advanced solid tumors resistant or refractory to standard therapy were eligible. The accelerated titration design of the trial involved two phases for evaluation of schedule and dose: 1) fixed dose with increasing duration, and 2) dose escalation over a fixed duration (28 days). Results: 16 pts (median age: 64.5 years [range 48.8–80.1], 13M/3F)were treated with once daily doses ranging from 10mg to 130mg. The first four patients received a 10mg dose for 7, 14, 21 or 28 days respectively. Five subsequent cohorts received 28 days continuous dosing, with dose doubling in single patient cohorts until drug-related toxicity ≥ Grade 2. Thereafter dose was escalated in ≤ 40% increments in 3-patient cohorts. The most frequent adverse events were: gr 1–2 thrombocytopenia (44%), gr 1 diarrhea (25%), gr 1–2 transaminitis (19%), gr 1–2 fatigue (13%), gr 1 hot flushes (13%), and gr 1 lightheadedness (13%). There were no DLTs. Five patients continued therapy after 28 days; stable disease has been achieved in 1 pt for 6 months with granulosa cell carcinoma of ovary, who was progressing prior to study entry. CHR-2797 and CHR-79888 demonstrate dose proportional increases in AUC and Cmax. The terminal half-life for CHR-2797 is around 1–2 hours, whereas it is between 9 and 11 hours for CHR-79888. Intracellular (packed blood cells) exposure to both CHR-2797 and CHR-79888 is good, with CHR-79888 accumulating over 28 days, such that by day 28 the intracellular levels are comparable to plasma. Conclusions: CHR-2797 is well tolerated and can be safely administered at doses that reach plasma concentrations associated with activity in pre-clinical models. Accrual into the study continues. No significant financial relationships to disclose.
SIGNIFICANCE OF MICROCIRCULATORY RESISTANCE IN VISUAL-FUNCTIONAL MISMATCH BETWEEN CORONARY ANGIOGRAPHY AND FRACTIONAL FLOW RESERVE IN NON-LEFT MAIN LESIONS
Authors: Eisuke Usui, Taishi Yonetsu, Tetsumin Lee, Tadashi Murai, Yoshihisa Kanaji, Masahiro Hoshino, Takayuki Niida, Masahiro Hada, Rikuta Hamaya, Mitsuaki Isobe, Tsunekazu Kakuta
Journal: Journal of the American College of Cardiology (2017)
Early results of limited resection for lung cancer equal to or less than 10mm
Authors: H.-E. Yoon
Journal: Journal of Clinical Oncology (2004)

7247 Background: With wide spread use of chest spiral computed tomography (CT), small early stage lung cancer has been increasingly found. It is important for improvement of lung cancer mortality that early detection is followed by early treatment. We prospectively performed wide wedge resection as curative procedure for the lung cancer equal to or less than (=<) 10 mm. We analyzed early results of limited resection for lung cancer =< 10 mm. Methods: From November 1999 to March 2003, 24 patients with lung cancer =< 10 mm underwent video-assisted thoracic surgery (VATS) in our institute. There were 9 males and 15 females. Mean age of the patients was 61 years old. None of lesions was not diagnosed preoperatively and diagnosed by intraoperative pathological examination. All but one VATS were done with preoperative CT- guided marking. In case of clear surgical margin, wide wedge resection was final procedure without lymph node sampling or dissection. In case of involved or indeterminate surgical margin, segmentectomy or lobectomy was added with lymph node sampling or dissection. For follow-up after surgery, patients underwent chest radiography every 3 months and chest CT every 6 months. Results: Mean size of the tumors was 7.1 mm. There were 22 adenocarcinomas, one squamous cell cancer and one small cell cancer. Twenty wedge resections, two segmentectomies (right basal segment and left Segment 8) and two lobectomies (right upper and right middle). No serious morbidity and mortality were found after operation. Applying perioperative care pathway for 14 patients, mean and median hospital stay after operation was 3 and 2 days. With mean follow-up time of 22 months, no recurrence was found. Conclusions: For lung cancer =< 10 mm, wedge resection could be curative operation. Because of high curability, low risks and low cost, we should be positive for resection of pulmonary nodule =< 10 mm suspected of malignancy by VATS. No significant financial relationships to disclose.
Crizotinib to overcome alectinib-resistance in non-small cell lung cancer (NSCLC) harboring EML4-ALK.
Authors: Hideko Isozaki, Eiki Ichihara, Nagio Takigawa, Toshiaki Sendo, Mitsune Tanimoto, Katsuyuki Kiura
Journal: Journal of Clinical Oncology (2015)

e19140 Background: Crizotinib, which is capable of blocking MET, ALK and ROS1, has been demonstrated the superior efficacy on first and second line therapy for advanced/metastatic patients with NSCLC harboring EML4-ALK fusion gene compared with chemotherapy. Alectinib, selective ALK inhibitor also has been showed dramatic response rate, long response duration and acceptable toxic profile (Lancet Oncol 14, 2013: 590-98). Two randomized clinical trials comparing alectinib with crizotinib in a first-line setting are ongoing. Alectinib would be a key drug of ALK-positive lung cancer treatment in the future. However, subsequent resistance to alectinib is expected after its approval. Thus, we need consider the therapeutic strategy to overcome the resistance to alectinib in advance. To elucidate the mechanisms of alectinib-resistance, we established resistant cell line and analyzed. Methods: Two alectinib-resistant ABC-11/CHR NSCLC cell lines from ABC-11 harboring EML4-ALK fusion genes were established by continuous exposure to alectinib. We characterized the resistant cell lines using MTT assay, Western blotting, immunohistochemistry, polymerase chain reaction, fluorescent in situ hybridization, phospho-receptor tyrosine kinase array, RNA array, ELISA and xenograft models. Results: ABC-11/CHR cells showed 17-fold more resistant than parent cells to alectinib by MTT assay. The resitant cells were activated MET with increment of its ligand (hepatocyte growth factor) as an autocrine action. Because crizotinib could inhibit MET as well as ALK, ABC-11/CHR cells were sensitive to the drug both in vitro and in vivo. Conclusions: We found that activation of MET caused to acquired resistance to alectinib. MET inhibitor combined with AKK inhibitor was effective on such case. Thus, ALK positive NSCLC patients with refractory to alectinib might have benefits from crizotinib.
Book Review / Announcement
Authors: Harold Levitan, Robert C. Smith, G.C. Lyketsos, A. Karabetsos, J. Jordanoglou, T. Liokis, A. Armagianidis, C.G. Lyketsos, Nancy L. Hutner, Steven E. Locke, Reinhold Schwarz, Siegfried Geyer, James Georgas, Eliza Giakoumaki, Nikos Georgoulias, Eugene Koumandakis, Dionysios Kaskarelis
Journal: Psychotherapy and Psychosomatics (1984)
Therapy Management Patient Consensus (TheMaPaC): A patient perspective on published therapy management recommendations for TKI-treated patients with a special focus on sunitinib.
Authors: Berit Eberhardt-Wetherington, Valerie Gall, Melanie Lang, Manuela Schmidinger, Viktor Gruenwald, Christina Claussen, Markus Wartenberg, Daniel Kalanovic
Journal: Journal of Clinical Oncology (2012)

e19502 Background: Therapy management is an essential component of patient care for RCC or GIST patients (pts) treated with TKI (e.g. Sunitinib). Preventive measures and early intervention can reduce or eliminate specific adverse events (AE) allowing for adequate therapy duration and improved quality of life. Published recommendations (RECs) for AE management often rely on theoretical aspects and limited evidence leading to heterogeneous or contradicting RECs. To overcome these issues, a collaborative approach of physicians, pts and Pfizer was established. Here we report on an extensive survey to deepen the knowledge on the validity and practicability of published RECs in 27 TKI treated pts (20 RCC; 7GIST). Methods: RECs (n = 221) for AE management in pts receiving sunitinib or other VEGFR-targeted TKIs were retrieved from the literature since 2006 (approval of sunitinib). RECs were transferred into a detailed questionnaire (QU) using patient-friendly language. Pts receiving sunitinib assigned one of 5 rating categories to each REC (positive experience (self/others); no information; negative experience (self/others). Results: 47 pts received the QU, 27 (15 female; median age 62 yrs) returned evaluable QUs. The pts have been on sunitinib therapy for a median of 16 months. On average, 49% of RECs received positive ratings; 44% based on individual experience. 20 RECs were rated positively by &gt;80% of pts. The results indicate that patients had the most positive experience with RECs about patient/physician information on AEs, care/protection of feet, skin ointment use, food preference, hydration and fatigue reduction. Other REC ratings were heterogeneous, with a preference for measures that can be easily applied in daily life. It is notable that 47% of published RECs were unknown to the participants. Conclusions: To our knowledge, this is the first extensive patient survey on the validity and practicability of published RECs. The results identify a number of useful, established RECs from a real-life pts perspective. The results will be further evaluated and compared with an ongoing physician survey.
Hyperthermic intrapleural chemotherapy combined with endostar by video-assisted thoracoscopic surgery for lung adenocarcinoma with pleural dissemination.
Authors: Lei Yu
Journal: Journal of Clinical Oncology (2012)

e17542 Background: Patients with lung adenocarcinoma and malignant pleural effusions have limited life expectancy. The treatment of lung adenocarcinoma with malignant pleural effusions remains controversial. The purpose of our study is to evaluate the use of video-assisted thoracoscopy to perform hyperthermic intrapleural chemotherapy combined with Endostar (recombinant human endostatin) for disseminated pleural adenocarcinoma. Methods: From 2007 to 2010, there were 46 patients with lung adenocarcinoma and pleural dissemination undergoing thoracoscopic surgery and intrathoracic hyperthermic perfusion with chemotherapy in combination of Endostar. After thoracoscopic surgery, the hyperthermic perfusion system was set up for hyperthermic intrapleural chemotherapy. The thoracic cavity was perfused at a speed of approximately 1.8-2.3 L/min with 0.9% normal saline (4-5L), containing cisplatinum (100 mg). The intrathoracic temperature remained between 42°C to 43°C. This process of perfusion lasted for 1 hours. Following this, 2L of 0.45% saline with Endostar (30 mg) at a temperature of 30 °C was put into the pleural cavity and kept for 30 min. Results: There were no peri-operative deaths. During the hyperthermic perfusion, patient's core temperature varied from 36.3ºC and 39.3ºC and pulse from 59 beats/m and 126 beats/m. Intraoperative sinus tachycardia occurred in 2 elderly cases. No hematologic toxicity and nephrotoxicity was observed within one week after surgery. Postoperative pneumonia occurred in 1 elderly case. The median survival time was 21 months. During the follow-up period, only one patient suffered from continuing pleural effusion due to atelectasis, one elderly patient died of heart failure one year after surgery and the remaining patients were completely free from pleural effusion during the last follow-up. Conclusions: Hyperthermic intrapleural chemotherapy combined with Endostar by thoracoscopic surgery offers a safe and effective treatment for lung adenocarcinoma with pleural dissemination. It may be time-consuming, but beneficial and may have an encouraging impact on its long-term survival.
SEX DIFFERENCES IN ATRIAL STRUCTURAL REMODELING AND SERUM MARKERS OF FIBROSIS AT PRESENTATION FOR CATHETER ABLATION
Authors: Jacqueline Denysiak, David Krummen, Hee-Kyung Chun, Taelor Getz, Meher N. Haque, Avinash Toomu, Gregory Feld, Jonathan Hsu, Lori Daniels
Journal: Journal of the American College of Cardiology (2017)
P53 Based Strategy to Reduce Hematological Toxicity of Chemotherapy: Emerging Support from a Phase II Trial
Authors: Chul S. Ha, Joel Michalek, Richard Elledge, Kevin R. Kelly, Suthakar Ganapathy, Hang Su, Carol Jenkins, Athanassios Argiris, Ronan Swords, Tony Y. Eng, Anand Karnad, Richard Crownover, Gregory P Swanson, Martin Goros, Brad H Pollock, Zhi-Min Yuan
Journal: Blood (2014)
Determinants of bronchial responsiveness in the European Community Respiratory Health Survey in Italy: evidence of an independent role of atopy, total serum IgE levels, and asthma symptoms
Journal: Allergy (1998)

The aim of the analysis was to test whether total serum IgE levels, specific serum IgE levels, and asthma symptoms are independent predictors of bronchial hyperresponsiveness (BHR), after controlling for known risk factors or potential confounders. The study was carried out on a sample of 875 young adults, 20–44 years old, who took part in the European Community Respiratory Health Survey in Italy The subjects underwent a dose‐response methacholine challenge test. We also measured airway caliber as the baseline FEV, in absolute terms and as percentage of forced vital capacity (FVC); skin wheal response to 11 common environmental allergens; and total and specific serum IgE levels to mites, molds, pets, and respiratory symptoms by means of a standardized questionnaire. Atopy (positive skin prick test and/or positive specific IgE assay), total IgE, asthma symptoms, airway caliher, and age appeared to be independent predictors of BHR. When all the other risk factors were taken into account, atopy and total IgE were associated with a threefold increase in BHR risk and thus emerged as the main determinants of BHR. The importance of symptom status as a determinant of BHR decreased remarkably after controlling for atopy and IgE: the odds ratio of current asthmatics to asymptomatic subjects decreased from 15.3 to 8.8. When controlling for symptoms and atopy, a family history of allergic diseases and early respiratory infections was not found to be associated with BHR. Both FEVi and FEV/FVC were strongly and inversely associated with BHR. When airway caliher was taken into account, older age was associated with decreased responsiveness, and the level of responsiveness did not differ significantly between males and females and between smokers and nonsmokers. The results from this analysis indicate that at any given age, irrespective of sex and smoking habits, total serum IgE, specific IgE, airway caliber, and asthma symptoms are the main independent factors influencing the occurrence of BHR in a young adult sample.
International experts' practice in the antibiotic therapy of infective endocarditis is not following the guidelines
Authors: H. Tissot-Dupont, J.P. Casalta, F. Gouriet, S. Hubert, E. Salaun, G. Habib, M.P. Fernandez-Gerlinger, J.L. Mainardi, P. Tattevin, M. Revest, F. Lucht, E. Botelho-Nevers, A. Gagneux-Brunon, U. Snygg-Martin, K.L. Chan, J. Bishara, I. Vilacosta, C. Olmos, J.A. San Román, J. López, P. Tornos, N. Fernández-Hidalgo, E. Durante-Mangoni, R. Utili, M. Paul, L.M. Baddour, D.C. DeSimone, M.R. Sohail, J.M. Steckelberg, W.R. Wilson, D. Raoult
Journal: Clinical Microbiology and Infection (2017)
Gemcitabine by hepatic artery chemoembolization for unresectable hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCC)
Authors: D. A. Geller, W. Marsh, B. I. Carr
Journal: Journal of Clinical Oncology (2004)

4158 Background: There are no drugs that have accepted response rates for unresectable cholangiocarcinoma and the presence of underlying cirrhosis in about 80 % of patients with HCC, makes regional chemotherapy hazardous. New chemotherapeutic agents need to be identified that are less toxic to the liver that has already been damaged by chronic hepatitis or cirrhosis. Method: Gemcitabine was evaluated for its safety and effectiveness in 44 pts with CC and 30 pts with HCC, with bilirubin grade I hematologic toxicity was seen in any pt. No pt went into irreversible liver failure. However, 8 of 30 pts with HCC had transient elevations of bilirubin. No pts with CC had any hepatic toxicity. Results: CT responses were often difficult to estimate for CC, since central lesions were often ill-defined on any non-invasive radiologic study. However, 8 CC pts are alive > 24 mo, 15 pts are alive at 12–24 mo, 14 pts died at 6–12 mo and 7 pts died at 6 mo. Currently, 6 pts have died, all > 3 mo and < 9 mo and all from tumor progression. Conclusions: these initial results show that TACE with Gemcitabine is safe, even in the liver with cirrhosis, provided that the starting bilirubin is < 1.5 mg/dL and can result in partial responses. It looks particularly interesting for pts with unresectable CC. Longer follow-up will determine the survival effects. No significant financial relationships to disclose.
PREVALENCE OF ELEVATED BODY MASS INDEX AND ITS ASSOCIATION WITH CLINICAL FEATURES IN ADULT FONTAN PATIENTS
Authors: Anushree Agarwal, Aarthi Sabanayagam, Ahmed Kheiwa, Colin Cunnington, Lucas Zier, Charles McCulloch, Ian Harris, Elyse Foster, Dougal Atkinson, Angela Bryan, Petra Jenkins, Jaspal Dua, Michael Parker, Devinda Karunaratne, John A. Moore, Jeffery Meadows, Bernard Clarke, J. Andreas Hoschtitzky, Vaikom Mahadevan
Journal: Journal of the American College of Cardiology (2017)
CAROTID PLAQUE INFLAMMATION IN PATIENTS WITH DIABETES MELLITUS AND CORONARY ARTERY DISEASE
Authors: Georgios Tzanis, Maria Bonou, Georgios Benetos, Smaragda Biliou, Stavros Liatis, Elias Sanidas, Konstantinos Toutouzas, John Barbetseas, Cardiology Department
Journal: Journal of the American College of Cardiology (2017)